Novel Immunologic Approaches to Melanoma Treatment

Actas Dermosifiliogr. 2017 Oct;108(8):708-720. doi: 10.1016/j.ad.2017.01.017. Epub 2017 May 18.
[Article in English, Spanish]

Abstract

Approaches to treating melanoma have changed radically since the introduction of immunotherapy, and survival figures are now higher than possible with earlier therapies. The immunomodulators currently available mainly block CTLA-4 (cytotoxicT lymphocyte-associated molecule-4) and PD-1 (programed cell death protein 1) translocated to the cell surface, where they inhibit the antitumor immune response. Treatments blocking these molecules are being more widely used. Research now seeks new molecular targets, the best combinations of available drugs, and biomarkers that can identify ideal candidates for each one.

Keywords: Clinical oncology; Immunology; Immunotherapy; Inmunología; Inmunoterapia; Melanoma; Oncología clínica.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antigens, Neoplasm / immunology
  • B7-H1 Antigen / antagonists & inhibitors
  • B7-H1 Antigen / immunology
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / immunology
  • Clinical Trials as Topic
  • Cytokines / metabolism
  • Forecasting
  • Humans
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use
  • Immunotherapy / methods*
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology
  • Lymphocytes, Tumor-Infiltrating / drug effects
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Macrophages / metabolism
  • Melanoma / immunology
  • Melanoma / secondary
  • Melanoma / therapy*
  • Mice
  • Oncolytic Virotherapy
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology
  • Salvage Therapy
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Therapies, Investigational*
  • Tumor Escape / drug effects
  • Tumor Escape / immunology

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • B7-H1 Antigen
  • CD274 protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Cytokines
  • Immunologic Factors
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor